Gobardhan Das
Overview
Explore the profile of Gobardhan Das including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
2097
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singh B, Pahuja I, Yadav P, Shaji A, Chaturvedi S, Ranganathan A, et al.
J Infect Dis
. 2023 Oct;
229(5):1509-1518.
PMID: 37863472
Tuberculosis is the second leading infectious killer after coronavirus disease 2019 (COVID-19). Standard antitubercular drugs exhibit various limitations like toxicity, long treatment regimens, and lack of effect against dormant and...
2.
Singh D, Bhaskar A, Pahuja I, Shaji A, Moitra B, Shi Y, et al.
J Infect Dis
. 2023 Jun;
228(9):1166-1178.
PMID: 37290049
Mycobacterium tuberculosis, the causative agent of tuberculosis, is acquiring drug resistance at a faster rate than the discovery of new antibiotics. Therefore, alternate therapies that can limit the drug resistance...
3.
Devi A, Pahuja I, Singh S, Verma A, Bhattacharya D, Bhaskar A, et al.
Cell Mol Immunol
. 2023 May;
20(6):600-612.
PMID: 37173422
Mesenchymal stem cells (MSCs) play diverse roles ranging from regeneration and wound healing to immune signaling. Recent investigations have indicated the crucial role of these multipotent stem cells in regulating...
4.
Chaurasiya A, Kumari G, Garg S, Shoaib R, Anam Z, Joshi N, et al.
Antimicrob Agents Chemother
. 2022 Nov;
66(12):e0039222.
PMID: 36374050
The emergence of Plasmodium falciparum resistance raises an urgent need to find new antimalarial drugs. Here, we report the rational repurposing of the anti-hepatitis C virus drug, alisporivir, a nonimmunosuppressive...
5.
Singh M, Kumar S, Singh B, Jain P, Kumari A, Pahuja I, et al.
Commun Biol
. 2022 Jul;
5(1):759.
PMID: 35902694
Directly Observed Treatment Short-course (DOTs), is an effective and widely recommended treatment for tuberculosis (TB). The antibiotics used in DOTs, are immunotoxic and impair effector T cells, increasing the risk...
6.
Singh D, Dwivedi V, Singh S, Kumari A, Sharma S, Ranganathan A, et al.
PLoS Pathog
. 2021 Aug;
17(8):e1009896.
PMID: 34460866
[This corrects the article DOI: 10.1371/journal.ppat.1008887.].
7.
Singh D, Tousif S, Bhaskar A, Devi A, Negi K, Moitra B, et al.
PLoS Pathog
. 2021 Aug;
17(8):e1009805.
PMID: 34415976
Tuberculosis (TB) remains a major health problem throughout the world with one third of the population latently infected and ~1.74 million deaths annually. Current therapy consists of multiple antibiotics and...
8.
Kumar S, Bhaskar A, Patnaik G, Sharma C, Singh D, Kaushik S, et al.
JCI Insight
. 2021 Jan;
6(4).
PMID: 33444288
Prime-boost immunization strategies are required to control the global tuberculosis (TB) pandemic, which claims approximately 3 lives every minute. Here, we have generated an immunogenic complex against Mycobacterium tuberculosis (M.tb),...
9.
Chaurasiya A, Garg S, Khanna A, Narayana C, Dwivedi V, Joshi N, et al.
Cell Death Discov
. 2021 Jan;
7(1):10.
PMID: 33441562
Hijacking of host metabolic status by a pathogen for its regulated dissemination from the host is prerequisite for the propagation of infection. M. tuberculosis secretes an NAD-glycohydrolase, TNT, to induce...
10.
Singh D, Dwivedi V, Singh S, Kumari A, Sharma S, Ranganathan A, et al.
PLoS Pathog
. 2020 Sep;
16(9):e1008887.
PMID: 32956412
Despite the availability of multiple antibiotics, tuberculosis (TB) remains a major health problem worldwide, with one third of the population latently infected and ~2 million deaths annually. The only available...